表紙
市場調査レポート

PharmaPoint:ヒト免疫不全ウイルス (HIV) - 世界の医薬品市場の2023年までの予測と市場分析

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 346487
出版日 ページ情報 英文 461 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
PharmaPoint:ヒト免疫不全ウイルス (HIV) - 世界の医薬品市場の2023年までの予測と市場分析 PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023
出版日: 2015年09月09日 ページ情報: 英文 461 Pages
概要

ヒト免疫不全ウイルス (HIV) は、免疫系の細胞に感染するレトロウイルスで、その機能を破壊したり、損ないます。感染が進行すると、免疫系はますます弱くなり、感染者はその他の感染症の影響を受けやすくなります。

当レポートでは、世界のHIV治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因
  • 病態生理
  • 病期と症状
  • 予後
  • QOL

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • EU5ヶ国
    • ブラジル、中国、日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 主要8か国のHIVの疫学予測
    • 有病者総数
    • 有病者総数:年齢別
    • 有病者総数:性別
    • 有病者総数:年齢調整
    • 抗レトロウイルス療法 (ART)
    • 妊婦
  • 日本のHIVの疫学予測
    • HIVと診断された有病者数
    • HIVと診断された有病者数:年齢別
    • HIVと診断された有病者数:性別
    • HIVと診断された有病者数:年齢調整
    • 抗レトロウイルス療法 (ART)
    • 妊婦
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断と治療の概要
  • 米国
  • EU5ヶ国
  • 日本
  • ブラジル
  • 中国

第6章 競合評価

第7章 アンメットニーズと機会

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 後期開発中の有望な薬剤
  • 初期開発中の有望な薬剤
  • その他

第9章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Gilead Sciences
    • ViiV Healthcare
    • AbbVie
    • Merck & Co.
    • Janssen
    • Bristol-Myers Squibb
    • 日本たばこ産業
    • Avexa
    • TaiMed Biologics
    • Tobira Therapeutics

第10章 市場の見通し

  • 世界市場
  • 米国
  • EU5ヶ国
  • 日本
  • ブラジル
  • 中国

第11章 付録

図表

目次
Product Code: GDHC94PIDR

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline's (GSK's) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

GlobalData projects the global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcare's Triumeq (dolutegravir/abacavir/lamivudine), Gilead's Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gilead's and Janssen's darunavir/cobicistat/emtricitabine/TAF. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Highlights

Key Questions Answered

  • How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2013-2023?
  • What are the most promising late-stage pipeline drugs in HIV?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
  • What are the unmet needs in HIV treatment management?
  • What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Key Findings

  • The global HIV therapeutics market was worth approximately $14 billion in 2013, and GlobalData projects this market to reach a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These sales are expected to come predominantly from the US market, as financial austerity measures remain a primary barrier to the growth of the HIV market in the other countries covered in this report.
  • Over GlobalData's 2013-2023 forecast period, the increased uptake of STRs is expected to drive market growth. KOLs interviewed by GlobalData expect that INI-based STRs - led by ViiV's Triumeq and Gilead's Quad 2 - will dominate the marketplace for the duration of the forecast period.
  • The most notable barriers of growth over the forecast period include patent expiries of key HIV drugs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan) and compulsory licensing in Brazil and China.

Scope

  • Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline HIV market revenue from 2013-2023. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology
    • 3.1.1. Viral Lifecycle
  • 3.2. Pathophysiology
  • 3.3. Staging and Symptoms
    • 3.3.1. Primary or Acute Infection
    • 3.3.2. Chronic Infection
    • 3.3.3. Advanced Infection/AIDS
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Brazil, China, and Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for HIV in the 8MM (2013-2023)
    • 4.5.1. Total Prevalent Cases of HIV
    • 4.5.2. Age-Specific Total Prevalent Cases of HIV
    • 4.5.3. Sex-Specific Total Prevalent Cases of HIV
    • 4.5.4. Age-Standardized Total Prevalence of HIV
    • 4.5.5. HIV Cases Treated with ART
    • 4.5.6. Cases of HIV in Pregnant Women
  • 4.6. Epidemiological Forecast for HIV in Japan (2013-2023)
    • 4.6.1. 20-Year Diagnosed Prevalent Cases of HIV
    • 4.6.2. Age-Specific 20-Year Diagnosed Prevalent Cases of HIV
    • 4.6.3. Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV
    • 4.6.4. Age-Standardized 20-Year Diagnosed Prevalence of HIV
    • 4.6.5. HIV Cases Treated with ART
    • 4.6.6. Cases of HIV in Pregnant Women
  • 4.7. Discussion
    • 4.7.1. Epidemiological Forecast Insight
    • 4.7.2. Limitations of the Analysis
    • 4.7.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Screening and Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
    • 5.2.1. Screening and Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. 5EU
    • 5.3.1. Screening and Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Japan
    • 5.4.1. Screening and Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Brazil
    • 5.5.1. Screening and Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. China
    • 5.6.1. Screening and Diagnosis
    • 5.6.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands, Single-Tablet Regimens (STRs)
    • 6.2.1. Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
    • 6.2.2. Complera (emtricitabine/TDF/rilpivirine)
    • 6.2.3. Stribild (elvitegravir/cobicistat/TDF/emtricitabine)
    • 6.2.4. Triumeq (dolutegravir/abacavir/lamivudine)
  • 6.3. Product Profiles - Major Brands, Fixed-Dose Combinations
    • 6.3.1. Truvada (TDF/emtricitabine)
    • 6.3.2. Epzicom (abacavir/lamivudine)
    • 6.3.3. Kaletra (lopinavir/ritonavir)
    • 6.3.4. Prezcobix (darunavir/cobicistat)
    • 6.3.5. Evotaz (atazanavir sulfate/cobicistat)
  • 6.4. Product Profiles - Major Brands, Protease Inhibitors
    • 6.4.1. Reyataz (atazanavir)
    • 6.4.2. Prezista (darunavir)
  • 6.5. Product Profiles - Major Brands, Integrase Inhibitors
    • 6.5.1. Isentress (raltegravir)
    • 6.5.2. Tivicay (dolutegravir)
    • 6.5.3. Vitekta (elvitegravir)
  • 6.6. Product Profiles - Major Brands, Pharmacokinetic Enhancers
    • 6.6.1. Norvir (ritonavir)
    • 6.6.2. Tybost (cobicistat)
  • 6.7. Other Therapeutic Classes
    • 6.7.1. Entry Inhibitors

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Therapies with Improved Safety and Tolerability Profiles
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Simplified PI-Based ART Regimens with a Reduced Pill Burden
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Enhanced Public Awareness Initiatives Focused on Minimizing the Stigma Associated with HIV
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Improved Physician Education Tools That Emphasize the Importance of Early Testing and Diagnosis
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Safe and Efficacious Therapies for Patients with Drug-Resistant HIV Strains
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Long-Acting Regimens That Require Less Frequent Administration
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity
  • 7.8. Improved Access to Treatment
    • 7.8.1. Unmet Need
    • 7.8.2. Gap Analysis
    • 7.8.3. Opportunity
  • 7.9. Progress Towards a Functional Cure
    • 7.9.1. Unmet Need
    • 7.9.2. Gap Analysis
    • 7.9.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Promising Drugs in Late-Stage Clinical Development
    • 8.3.1. Quad 2(elvitegravir/cobicistat/emtricitabine/TAF)
    • 8.3.2. Darunavir/Cobicistat/Emtricitabine/TAF
    • 8.3.3. Emtricitabine/TAF
    • 8.3.4. Dutrebis (raltegravir/lamivudine)
    • 8.3.5. Doravirine (MK-1439)
  • 8.4. Promising Drugs in Early-Stage Clinical Development
  • 8.5. Other Drugs in Clinical Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Gilead Sciences
    • 9.3.2. ViiV Healthcare
    • 9.3.3. AbbVie
    • 9.3.4. Merck & Co.
    • 9.3.5. Janssen
    • 9.3.6. Bristol-Myers Squibb
    • 9.3.7. Japan Tobacco
    • 9.3.8. Avexa
    • 9.3.9. TaiMed Biologics
    • 9.3.10. Tobira Therapeutics

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Brazil
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. China
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Total Prevalent Cases of HIV
    • 11.4.2. 20-Year Diagnosed Prevalent Cases of HIV
    • 11.4.3. HIV Cases Treated with ART
    • 11.4.4. Drugs Included in Each Therapeutic Class
    • 11.4.5. Launch and Patent Expiry Dates
    • 11.4.6. General Pricing Assumptions
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Epidemiologists
    • 11.7.3. Therapy Area Director
    • 11.7.4. Global Director of Therapy Analysis and Epidemiology
    • 11.7.5. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of HIV-1 Infection and AIDS
  • Table 2: Risk Factors and Comorbidities for HIV
  • Table 3: US, Total Prevalence of HIV in Men and Women (%), Age ≥13 Years, 2006-2010
  • Table 4: 5EU, Total Prevalence of HIV in Men (%), All Ages, Selected Years, 2001-2013
  • Table 5: 5EU, Total Prevalence of HIV in Women (%), All Ages, Selected Years, 2001-2013
  • Table 6: 8MM, Sources Used to Forecast theTotal Prevalent Cases of HIV
  • Table 7: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan
  • Table 8: 9MM, Sources Used to Forecast the ART Treatment Rate Among the Total Prevalent Cases of HIV
  • Table 9: 9MM, Sources Used to Forecast the Prevalent Cases of HIV-Positive Pregnant Women
  • Table 10: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023
  • Table 11: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N (Row %), 2013
  • Table 12: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N (Row %), 2013
  • Table 13: 8MM, HIV Cases Treated with ART, N (Col %), All Ages, Both Sexes, Selected Years 2013-2023
  • Table 14: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023
  • Table 15: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N (Row %), 2013
  • Table 16: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N (Row %), 2013
  • Table 17: Japan, HIV Cases Treated with ART, All Ages, Both Sexes, N, Selected Years 2013-2023
  • Table 18: Treatment Guidelines for HIV-1 Used in the 9MM
  • Table 19: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2013
  • Table 20: Diagnosis and Treatment of HIV Infection, Country Profile - US
  • Table 21: Switching of ART Regimens in the US, 2013
  • Table 22: Diagnosis and Treatment of HIV Infection, Country Profile - 5EU
  • Table 23: CD4+ Thresholds and Corresponding Recommendations for the Initiation of ART in Asymptomatic Patients in the 5EU
  • Table 24: Switching of ART Regimens in the 5EU, 2013
  • Table 25: Diagnosis and Treatment of HIV Infection, Country Profile - Japan
  • Table 26: Switching of ART Regimens in Japan, 2013
  • Table 27: Diagnosis and Treatment of HIV Infection, Country Profile - Brazil
  • Table 28: Switching of ART Regimens in Brazil. 2013
  • Table 29: Diagnosis and Treatment of HIV Infection, Country Profile - China
  • Table 30: Switching of ART Regimens in China, 2013
  • Table 31: Leading Branded Treatments for HIV, 2013
  • Table 32: Product Profile - Atripla
  • Table 33: Antiviral Efficacy of Atripla Compared with Combivir-Efavirenz Combination Therapy
  • Table 34: Atripla's Safety - Adverse Reactions Reported in a 144-Week Clinical Study
  • Table 35: Atripla SWOT Analysis, 2014
  • Table 36: Sales Forecasts ($m) for Atripla, 2013-2023
  • Table 37: Product Profile - Complera
  • Table 38: ECHO and THRIVE Studies of the Complera and Atripla Multi-Tablet Regimens
  • Table 39: Complera SWOT Analysis, 2014
  • Table 40: Sales Forecasts ($m) for Complera, 2013-2023
  • Table 41: Product Profile - Stribild
  • Table 42: Pivotal Phase III Trials of Stribild in Treatment-NaIve Patients
  • Table 43: Stribild's Adverse Reactions - Pooled Results From the Two Phase III Clinical Trials
  • Table 44: Stribild SWOT Analysis, 2014
  • Table 45: Sales Forecasts ($m) for Stribild, 2013-2023
  • Table 46: Product Profile - Triumeq
  • Table 47: Virologic Efficacy of Triumeq in the Phase III SINGLE Study
  • Table 48: Triumeq's Safety - Adverse Reactions Reported at 96 Weeks in the SINGLE Study
  • Table 49: Triumeq SWOT Analysis, 2014
  • Table 50: Sales Forecasts ($m) for Triumeq, 2013-2023
  • Table 51: Product Profile - Truvada
  • Table 52: Truvada's Efficacy - Results of the SWIFT Trial at 48 Weeks
  • Table 53: Truvada SWOT Analysis, 2014
  • Table 54: Sales Forecasts ($m) for Truvada, 2013-2023
  • Table 55: Product Profile - Epzicom
  • Table 56: Epzicom SWOT Analysis, 2014
  • Table 57: Sales Forecasts ($m) for Epzicom, 2013-2023
  • Table 58: Product Profile - Kaletra
  • Table 59: Kaletra SWOT Analysis, 2014
  • Table 60: Sales Forecasts ($m) for Kaletra, 2013-2023
  • Table 61: Product Profile - Prezcobix
  • Table 62: Efficacy of Prezcobix in the Phase III Trial
  • Table 63: Prezcobix SWOT Analysis, 2014
  • Table 64: Sales Forecasts ($m) for Prezcobix, 2013-2023
  • Table 65: Product Profile - Evotaz
  • Table 66: Efficacy of BMS' Evotaz in the Phase III Study
  • Table 67: Evotaz SWOT Analysis, 2014
  • Table 68: Sales Forecasts ($m) for Evotaz, 2013-2023
  • Table 69: Product Profile - Reyataz
  • Table 70: Reyataz SWOT Analysis, 2014
  • Table 71: Sales Forecasts ($m) for Reyataz, 2013-2023
  • Table 72: Product Profile - Prezista
  • Table 73: Prezista SWOT Analysis, 2014
  • Table 74: Sales Forecasts ($m) for Prezista, 2013-2023
  • Table 75: Product Profile - Isentress
  • Table 76: Percentage of Patients with HIV-1 RNA Levels <50 Copies/mL from the SMARTMRK Study
  • Table 77: Isentress' Safety - Adverse Reactions Reported in the SMARTMRK Study
  • Table 78: Isentress SWOT Analysis, 2014
  • Table 79: Sales Forecasts ($m) for Isentress, 2013-2023
  • Table 80: Product Profile - Tivicay
  • Table 81: Pivotal Phase III Trials of Tivicay
  • Table 82: Tivicay's Safety - Adverse Reactions Reported in the 48-Week SINGLE Study
  • Table 83: Tivicay SWOT Analysis, 2014
  • Table 84: Sales Forecasts ($m) for Tivicay, 2013-2023
  • Table 85: Product Profile - Vitekta
  • Table 86: Efficacy of Vitekta in the Pivotal Phase III Clinical Study
  • Table 87: Vitekta's Safety - Adverse Reactions Reported in the 96-Week Clinical Study
  • Table 88: Vitekta SWOT Analysis, 2014
  • Table 89: Sales Forecasts ($m) for Vitekta, 2013-2023
  • Table 90: Product Profile - Norvir (ritonavir)
  • Table 91: Norvir SWOT Analysis, 2014
  • Table 92: Sales Forecasts ($m) for Norvir, 2013-2023
  • Table 93: Product Profile - Tybost
  • Table 94: Efficacy of Tybost Versus Ritonavir as a Pharmacoenhancer of Atazanavir in the Phase III Trial
  • Table 95: Tybost SWOT Analysis, 2014
  • Table 96: Sales Forecasts ($m) for Tybost, 2013-2023
  • Table 97: Summary of the Minor Therapeutic Classes of EIs, 2014
  • Table 98: Unmet Need and Opportunity in HIV
  • Table 99: Promising Drugs in Clinical Development for HIV, 2014
  • Table 100: Comparison of Therapeutic Classes in Development for HIV, 2013-2023
  • Table 101: Gilead's Quad 2 - Phase III Clinical Trials
  • Table 102: Product Profile - Quad 2
  • Table 103: Efficacy of Quad 2 and Stribild in Studies 104 and 111
  • Table 104: Adverse Events Associated with Quad 2 vs. Stribild Therapy in two Phase III Clinical Studies
  • Table 105: Renal and Bone Safety of Quad 2 Versus Stribild Treatment in the Two Pivotal Phase III Studies
  • Table 106: Quad 2 SWOT Analysis, 2014
  • Table 107: Sales Forecasts ($m) for Quad 2, 2013-2023
  • Table 108: Product Profile - Darunavir/cobicistat/emtricitabine/TAF
  • Table 109: Efficacy of Darunavir/Cobicistat/Emtricitabine/TAF in the Phase II Study
  • Table 110: Safety of Darunavir/Cobicistat/Emtricitabine/TAF - Adverse Reactions Reported at 48 Weeks in the Phase II Study
  • Table 111: Renal and Bone Safety of Darunavir/Cobicistat/Emtricitabine/TAF in the Phase II Study
  • Table 112: Darunavir/Cobicistat/Emtricitabine/TAF SWOT Analysis, 2014
  • Table 113: Sales Forecasts ($m) for Darunavir/Cobicistat/Emtricitabine/TAF, 2013-2023
  • Table 114: Product Profile - Emtricitabine/TAF
  • Table 115: Two Pivotal Clinical Trials of Emtricitabine/TAF
  • Table 116: Phase III Clinical Trials Assessing the Safety of Emtricitabine/TAF
  • Table 117: Emtricitabine/TAF SWOT Analysis, 2014
  • Table 118: Sales Forecasts ($m) for Emtricitabine/TAF, 2013-2023
  • Table 119: Product Profile - Dutrebis
  • Table 120: Percentage of Patients with HIV-1 RNA Levels of <50 Copies/mL in the SMARTMRK Study
  • Table 121: Dutrebis SWOT Analysis, 2014
  • Table 122: Sales Forecasts ($m) for Dutrebis, 2013-2023
  • Table 123: Product Profile - Doravirine
  • Table 124: Efficacy Results of a Phase II Dose-Ranging Study of Doravirine Compared with a Standard Dose of Efavirenz
  • Table 125: Doravirine SWOT Analysis, 2014
  • Table 126: Sales Forecasts ($m) for Doravirine, 2013-2023
  • Table 127: Promising Drugs in Early-Stage Clinical Development for HIV, 2014
  • Table 128: Other Earlier-Stage Drugs in Active Clinical Development for HIV, 2014
  • Table 129: Key Companies in the HIV-1 Market in the 9MM, 2014
  • Table 130: Gilead Sciences' HIV Portfolio Assessment, 2014
  • Table 131: Gilead Sciences, SWOT Analysis in HIV, 2013-2023
  • Table 132: ViiV Healthcare's HIV Portfolio Assessment, 2014
  • Table 133: ViiV Healthcare, SWOT Analysis in HIV, 2013-2023
  • Table 134: AbbVie's HIV Portfolio Assessment, 2014
  • Table 135: AbbVie, SWOT Analysis in HIV, 2013-2023
  • Table 136: Merck & Co.'s HIV Portfolio Assessment, 2014
  • Table 137: Merck & Co., SWOT Analysis in HIV, 2013-2023
  • Table 138: Janssen's HIV Portfolio Assessment, 2014
  • Table 139: Janssen, SWOT Analysis in HIV, 2013-2023
  • Table 140: BMS' HIV Portfolio Assessment, 2014
  • Table 141: BMS, SWOT Analysis in HIV, 2013-2023
  • Table 142: Japan Tobacco's HIV Portfolio Assessment, 2014
  • Table 143: Japan Tobacco, SWOT Analysis in HIV, 2013-2023
  • Table 144: Avexa's HIV Portfolio Assessment, 2014
  • Table 145: Avexa, SWOT Analysis in HIV, 2013-2023
  • Table 146: TaiMed Biologics, HIV Portfolio Assessment, 2014
  • Table 147: TaiMed Biologics, SWOT Analysis in HIV, 2013-2023
  • Table 148: Tobira Therapeutics, HIV Portfolio Assessment, 2014
  • Table 149: Tobira Therapeutics, SWOT Analysis in HIV, 2013-2023
  • Table 150: Global Sales Forecasts ($m) for HIV Therapeutics, 2013-2023
  • Table 151: Global HIV Therapeutics Market - Drivers and Barriers, 2013-2023
  • Table 152: Sales Forecasts ($m) for HIV Therapeutics in the US, 2013-2023
  • Table 153: Key Events Impacting Sales of HIV Therapeutics in the US, 2013-2023
  • Table 154: HIV Therapeutics Market in the US - Drivers and Barriers, 2013-2023
  • Table 155: Number of People Living with HIV Who Received ART in the 5EU, and Sales of HIV Therapeutics, 2013
  • Table 156: Sales Forecasts ($m) for HIV Therapeutics in the 5EU, 2013-2023
  • Table 157: Key Events Impacting Sales of HIV Therapeutics in the 5EU, 2013-2023
  • Table 158: HIV Therapeutics Market in the 5EU - Drivers and Barriers, 2013-2023
  • Table 159: Financing of ART in the 5EU Countries by the National Healthcare Authorities
  • Table 160: Electronic Healthcare Systems Introduced in the 5EU Nations
  • Table 161: ART Initiation Criteria in the 5EU
  • Table 162: Systems Used to Control Drug Prices in the 55EU
  • Table 163: Sales Forecasts ($m) for HIV Therapeutics in Japan, 2013-2023
  • Table 164: Key Events Impacting Sales of HIV Therapeutics in Japan, 2013-2023
  • Table 165: HIV Therapeutics Market in Japan - Drivers and Barriers, 2013-2023
  • Table 166: Sales Forecasts ($m) for HIV Therapeutics in Brazil, 2013-2023
  • Table 167: Key Events Impacting Sales of HIV Therapeutics in Brazil, 2013-2023
  • Table 168: HIV Therapeutics Market in Brazil - Drivers and Barriers, 2013-2023
  • Table 169: Sales Forecasts ($m) for HIV Therapeutics in China, 2013-2023
  • Table 170: Key Events Impacting Sales of HIV Therapeutics in China, 2013-2023
  • Table 171: HIV Therapeutics Market in China - Drivers and Barriers, 2013-2023
  • Table 172: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM
  • Table 173: Key Historical and Projected Patent Expiry Dates for HIV Therapeutics Across the 9MM
  • Table 174: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: HIV Lifecycle
  • Figure 2: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023
  • Figure 3: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N, 2013
  • Figure 4: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N, 2013
  • Figure 5: 8MM, Age-Standardized Total Prevalence of HIV, All Ages, N, 2013
  • Figure 6: 8MM, Cases of HIV in Pregnant Women Among the Total Prevalent Cases of HIV in Women, N, 2013 and 2023
  • Figure 7: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023
  • Figure 8: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N, 2013
  • Figure 9: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N, 2013
  • Figure 10: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV, All Ages, N, 2013
  • Figure 11: Japan, Cases of HIV in Pregnant Women Among Diagnosed Prevalent Cases of HIV in Women, N, 2013 and 2023
  • Figure 12: HIV-1 Disease Management Flowchart
  • Figure 13: HIV Therapeutics - Phase II and III Clinical Trials by Country, 2014
  • Figure 14: HIV Phase II/Phase III Pipeline, 2014
  • Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2013-2023
  • Figure 16: Potential Clinical and Commercial Positioning of Quad 2
  • Figure 17: Potential Clinical and Commercial Positioning of Darunavir/Cobicistat/Emtricitabine/TAF
  • Figure 18: Potential Clinical and Commercial Positioning of Emtricitabine/TAF
  • Figure 19: Potential Clinical and Commercial Positioning of Dutrebis
  • Figure 20: Potential Clinical and Commercial Positioning of Doravirine
  • Figure 21: Company Portfolio Gap Analysis in HIV, 2013-2023
  • Figure 22: Global Sales for HIV Therapeutics by Country, 2013-2023
  • Figure 23: Global Sales for HIV Therapeutics by Drug Class, 2013-2023
  • Figure 24: Sales for HIV Therapeutics in the US by Drug Class, 2013-2023
  • Figure 25: Sales for HIV Therapeutics in the 5EU by Drug Class, 2013-2023
  • Figure 26: Sales for HIV Therapeutics in the 5EU by Country, 2013-2023
  • Figure 27: Sales for HIV Therapeutics in Japan by Drug Class, 2013-2023
  • Figure 28: Sales for HIV Therapeutics in Brazil by Drug Class, 2013-2023
  • Figure 29: Sales for HIV Therapeutics in China by Drug Class, 2013-2023
Back to Top